As of 6 Nov 2026, Earkart trades at 27.8× trailing earnings, below the industry P/E of 34.9×, and the shares are 52% below their 52-week high. It earns ROCE of 12% and ROE of 12%, and sales and net profit grew 23% and 55% a year over 3 years. The company has almost no debt. It is listed on an SME platform with a market cap of ₹153 Cr, ranked 7th of 9 Medical Devices companies by market cap; the shares fell 48% over the past year.
- ₹109.00
- ₹114.20
- ₹109.00
- ₹117.00
- 4K
Health check
- ReturnsBehind
−48.5% over a year, better than 1 of 7 peers.
- Price tagCheaper
P/E 27.8 vs industry 34.9.
- GrowthSteady
Sales +23.2%, profit +55.5% a year over 3 years.
- ProfitabilityAverage
ROCE 12.1% vs peer median 14.9%.
- Balance sheetStretched
Practically debt-free, Piotroski 3 of 9.
- Red flags1 to check
52% below its 52-week high.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹153 Cr
- Small cap
- P/E
- 27.8
- Industry 34.9
- Price to book
- 2.37
- Peers 4.08
- Dividend yield
- 0.00%
- ROE
- 11.7%
- Peers 10.7%
- ROCE
- 12.1%
- Peers 14.9%
- Debt to equity
- 0.00
- Debt ₹0.00 Cr
- EPS (TTM)
- ₹3.99
- OPM (TTM)
- 15.3%
- Net margin 9.1%
- Sales growth
- +60.8%
- Latest quarter vs a year ago
- Profit growth
- −9.2%
- Latest quarter vs a year ago
- Price to sales
- 2.82
- EV/EBITDA 15.9
Strengths and risks
Strengths
- Practically debt-free.
- Quarterly sales up 60.8% on a year ago.
Risks to check
- 52% below its 52-week high.
About Earkart
Earkart Limited manufactures and distributes modern hearing aids and related accessories in India and internationally. The company offers adjustable foldable walkers; Multi Sensory Inclusive Educational (MSIED) Kit designed for educational purpose for mentally retarded children; Teaching Learning Material (TLM) kits to support mobility and daily needs of physically challenged; and other rehabilitation products, including their components, accessories, and…
- Headquarters
- Noida
- Employees
- 58
- Sector
- Healthcare
- ISIN
- INE1A8F01035
- Website
- earkart.in
Price range
- Avg volume (3M)
- 1.8K
- 1-year return
- minus 48.5%
- From 52-week high
- minus 51.9%
Peers · Medical Devices
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOLBIOMolbio Diagnostics | 1,339.30 | minus 4.57% | 15,434 | 92.6 | 12.91 | 16.5% | 15.6% | 20.4% | 63.7% | – | 0.00% | plus 28.6% |
| SMTSahajanand Medical Technologies | 525.95 | plus 7.83% | 5,346 | 77.3 | 7.42 | 13.3% | 10.7% | 8.4% | – | – | 0.00% | plus 39.3% |
| FISCHERFischer Medical Ventures | 24.30 | minus 2.88% | 1,698 | 10.4 | 4.08 | 12.5% | 8.9% | 12.5% | 1097.3% | – | 0.21% | minus 73.4% |
| HSILHemant Surgical Industries | 628.65 | minus 0.21% | 914 | 42.1 | 5.95 | 19.5% | 18.1% | 10.0% | 28.4% | 33.5% | 0.00% | plus 117.2% |
| UNIVPHOTOUniversus Photo Imagings | 480.00 | minus 1.49% | 525 | – | 0.65 | −9.5% | −9.5% | 5.4% | −24.3% | – | 0.00% | plus 74.8% |
| NURECANureca | 302.30 | minus 0.30% | 302 | 61.4 | 1.53 | – | 2.5% | 8.3% | 9.7% | – | 0.00% | plus 17.4% |
| EARKARTEarkart | 111.00 | minus 5.13% | 153 | 27.8 | 2.37 | 12.1% | 11.7% | 15.3% | 23.2% | 55.5% | 0.00% | minus 48.5% |
| CHOKSIChoksi Asia | 210.35 | minus 0.71% | 120 | 23.1 | 2.85 | 18.4% | 13.5% | 14.5% | 309.2% | – | 0.00% | plus 99.0% |
| Median of 7 peers | – | −0.71% | 914 | 51.8 | 4.08 | 14.9% | 10.7% | 10.0% | 46.1% | 33.5% | 0.00% | 39.3% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- Sales CAGR 3Y
- +23.2%
- Profit CAGR 3Y
- +55.5%
- ROE
- 11.7%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 28.9 | 31.8 | 43.1 | 54 | |
| – | +9.8% | +35.7% | +25.4% | |
| 27.3 | 28.2 | 33.3 | 45.6 | |
| 1.6 | 3.6 | 9.8 | 8.5 | |
| 5.7% | 11.3% | 22.7% | 15.7% | |
| −0 | 0 | 0.1 | 0.1 | |
| 0 | 0.2 | 0.4 | 0.5 | |
| 0.2 | 0.2 | 0.4 | 0.8 | |
| −0 | −0 | – | – | |
| 1.5 | 3.2 | 9 | 7.3 | |
| 9.7% | 5.7% | 23.7% | 32.0% | |
| 1.3 | 3.1 | 6.9 | 4.9 | |
| – | +133.1% | +125.0% | minus 28.3% | |
| 0.95 | 2.22 | 5.00 | – |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 0.1 | 0.1 | 10.4 | 13.8 | |
| 6.5 | 12.9 | 9.5 | 50.6 | |
| 1.2 | 4 | 5 | 0 | |
| 7 | 2.2 | 5.4 | 5.1 | |
| 14.7 | 19.3 | 30.3 | 69.5 | |
| 0.2 | 0.8 | 1 | 5.1 | |
| 0.1 | 0.1 | 0.7 | – | |
| 0.6 | 1.4 | 0.4 | 21.7 | |
| 13.9 | 17 | 28.2 | 42.7 | |
| 14.7 | 19.3 | 30.3 | 69.5 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −0.3 | −1 | 0.7 | −12.6 | |
| 0.4 | −1.3 | −1.3 | −5.2 | |
| 0.4 | 3.1 | −0.4 | 39.1 | |
| 0.5 | 0.8 | −1 | 21.3 | |
| −0.2 | −1 | −0.5 | −5.4 | |
| −0.5 | −2 | 0.2 | −17.9 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders. Institutions hold about 3.0% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.